{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:49:47Z","timestamp":1789577387503,"version":"build-2803163510"},"reference-count":32,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Scleroderma and Related Disorders"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Systemic sclerosis is a severe autoimmune disease characterized by fibrosis of the skin and internal organs. Systemic sclerosis is associated with the presence of three specific autoantibodies: anti-topoisomerase I, anti-centromere, and anti-RNA polymerase III autoantibodies, which have also been identified as prognostic factors. However, it remains unknown whether the prognosis also varies based on their serum levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>We aimed to assess the value of serum levels of systemic sclerosis-specific autoantibodies as biomarkers of disease severity and progression in systemic sclerosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>We conducted a post hoc longitudinal analysis of data of systemic sclerosis patients included in the Zurich EUSTAR cohort, who were positive for at least one of the three systemic sclerosis-specific autoantibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The association between the levels of systemic sclerosis-specific autoantibodies and disease severity at baseline and during the follow-up was assessed by univariable and multivariable logistic and linear regressions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The serum levels of anti-topoisomerase I autoantibodies [\u03b2 =\u20090.032 (95% confidence interval = 0.014 to 0.049), p\u2009&lt;\u20090.001], anti-centromere [\u03b2\u2009=\u20090.002 (95% confidence interval = 0.001 to 0.003), p\u2009&lt;\u20090.001], and anti-RNA polymerase III autoantibodies [\u03b2\u2009=\u20090.143 (95% confidence interval = 0.066 to 0.220), p\u2009&lt;\u20090.001] were associated with the modified Rodnan Skin Score in univariable analysis at baseline. For anti-centromere [\u03b2 = 0.002 (95% confidence interval = 0.001 to 0.003), p\u2009&lt;\u20090.001] and anti-RNA polymerase III autoantibodies [\u03b2 = 0.135 (95% confidence interval = 0.053 to 0.217), p\u2009=\u20090.002], this association also remained significant in multivariable analysis. In the longitudinal analysis, the levels of the three systemic sclerosis-specific autoantibodies did not predict changes in mRSS over 1\u2009year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Increased serum levels of all three autoantibodies predicted a more severe skin fibrosis. The results underscore the relevance of measuring the levels of systemic sclerosis-specific autoantibodies to enhance risk stratification in systemic sclerosis, with particular focus on skin involvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23971983251357991","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T05:44:23Z","timestamp":1753767863000},"page":"342-349","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["The serum levels of specific autoantibodies in systemic sclerosis predict a more severe skin involvement"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4177-3779","authenticated-orcid":false,"given":"Hannah","family":"Dengler","sequence":"first","affiliation":[{"name":"Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Vonow-Eisenring","sequence":"additional","affiliation":[{"name":"Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike Oliver","family":"Becker","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rucsandra","family":"Dobrota","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8627-8817","authenticated-orcid":false,"given":"Carina","family":"Mihai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinziana","family":"Muraru","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"},{"name":"Department of Rheumatology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-8310","authenticated-orcid":false,"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Bruni","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-5758","authenticated-orcid":false,"given":"Muriel","family":"Elhai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker269"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211448"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31139"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1614915"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24038"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062901"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203716"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.38098"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(22)00217-X"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.5301\/jsrd.5000216"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.238"},{"key":"e_1_3_3_13_2","article-title":"Clinical phenotype in scleroderma patients based on autoantibodies","volume":"7","author":"Santos CS","year":"2023","unstructured":"Santos CS, Morales CM, Castro C\u00c1, et al. Clinical phenotype in scleroderma patients based on autoantibodies. Rheumatol Adv Pract 2023; 7(suppl 1): i26\u2013i33.","journal-title":"Rheumatol Adv Pract"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21232"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000904"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102602"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.42624"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.930970"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.10.1135"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10977"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003658"},{"issue":"7","key":"e_1_3_3_23_2","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy EC","year":"2001","unstructured":"LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28(7): 1573\u20131576.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.5301\/jsrd.5000231"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180503"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30318-0"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200005)43:5<1074::AID-ANR18>3.0.CO;2-E"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.01.032"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225174"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1615990113"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41814"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.05.011"}],"container-title":["Journal of Scleroderma and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23971983251357991","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23971983251357991","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23971983251357991","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T11:53:05Z","timestamp":1777981985000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23971983251357991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/23971983251357991"],"URL":"https:\/\/doi.org\/10.1177\/23971983251357991","relation":{},"ISSN":["2397-1983","2397-1991"],"issn-type":[{"value":"2397-1983","type":"print"},{"value":"2397-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]}}}